NASDAQ:AKTXAkari Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.01 +0.01 (+0.50 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$1.92Now: $2.01▼$2.0850-Day Range$1.16MA: $1.66▼$2.0352-Week Range$0.87Now: $2.01▼$3.35Volume241,451 shsAverage Volume306,529 shsMarket Capitalization$31.88 millionP/E RatioN/ADividend YieldN/ABeta-0.83 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAkari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Akari Therapeutics has a potential upside of 148.8% from its current price of $2.01.Amount of Analyst CoverageAkari Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAkari Therapeutics has received 257 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAkari Therapeutics has received 217 “underperform” votes. (Add your “underperform” vote.)Community SentimentAkari Therapeutics has received 54.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote “Outperform” if you believe AKTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAkari Therapeutics does not currently pay a dividend.Dividend GrowthAkari Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akari Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders61.80% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.10% of the stock of Akari Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akari Therapeutics are expected to remain at ($1.00) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akari Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akari Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKTX Previous Symbol CUSIPN/A CIK1541157 Webwww.akaritx.com Phone646-350-0702Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-18.27Profitability EPS (Most Recent Fiscal Year)($0.93) Net Income$-17,110,000.00 Net MarginsN/A Return on Equity-5,219.91% Return on Assets-220.20%Miscellaneous Employees17 Outstanding Shares15,860,000Market Cap$31.88 million Next Earnings Date6/3/2020 (Estimated) OptionableNot Optionable NASDAQ:AKTX Rates by TradingView Receive AKTX News and Ratings via Email Sign-up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions How has Akari Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Akari Therapeutics' stock was trading at $1.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AKTX shares have increased by 30.5% and is now trading at $2.01. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Akari Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akari Therapeutics. When is Akari Therapeutics' next earnings date? Akari Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for Akari Therapeutics. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics PLC (NASDAQ:AKTX) posted its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.25. View Akari Therapeutics' earnings history. What price target have analysts set for AKTX? 1 brokerages have issued 12 month price objectives for Akari Therapeutics' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Akari Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 148.8% from the stock's current price. View analysts' price targets for Akari Therapeutics. Has Akari Therapeutics been receiving favorable news coverage? Headlines about AKTX stock have trended neutral recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akari Therapeutics earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAkari Therapeutics. Who are some of Akari Therapeutics' key competitors? Some companies that are related to Akari Therapeutics include Aldeyra Therapeutics (ALDX), Checkpoint Therapeutics (CKPT), Axovant Gene Therapies (AXGT), Galmed Pharmaceuticals (GLMD), AcelRx Pharmaceuticals (ACRX), Cyclerion Therapeutics (CYCN), Humanigen (HGEN), Helix Biopharma (HBPCF), Theratechnologies (THERF), CELYAD SA/ADR (CYAD), InflaRx (LUMO), OASMIA PHARMACE/ADR (OASM), Recro Pharma (REPH), Corvus Pharmaceuticals (CRVS) and Catabasis Pharmaceuticals (CATB). View all competitors. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Novocure (NVCR), Teva Pharmaceutical Industries (TEVA), AbbVie (ABBV), Anavex Life Sciences (AVXL), Neurocrine Biosciences (NBIX) and Protalix Biotherapeutics (PLX). Who are Akari Therapeutics' key executives? Akari Therapeutics' management team includes the following people: Dr. Ray Prudo, Exec. Chairman (Age 74)Mr. Clive Richardson, COO, Director & Interim CEO (Age 54)Mr. Dov Elefant, Chief Financial Officer (Age 52)Dr. Miles Nunn, Chief Scientific Officer What is Akari Therapeutics' stock symbol? Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX." Who are Akari Therapeutics' major shareholders? Akari Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Omnia Family Wealth LLC (1.16%). View institutional ownership trends for Akari Therapeutics. Which institutional investors are buying Akari Therapeutics stock? AKTX stock was purchased by a variety of institutional investors in the last quarter, including Omnia Family Wealth LLC. View insider buying and selling activity for Akari Therapeutics. How do I buy shares of Akari Therapeutics? Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Akari Therapeutics' stock price today? One share of AKTX stock can currently be purchased for approximately $2.01. How big of a company is Akari Therapeutics? Akari Therapeutics has a market capitalization of $31.88 million. The biopharmaceutical company earns $-17,110,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Akari Therapeutics employs 17 workers across the globe. What is Akari Therapeutics' official website? The official website for Akari Therapeutics is www.akaritx.com. How can I contact Akari Therapeutics? Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 646-350-0702 or via email at [email protected] This page was last updated on 5/24/2020 by MarketBeat.com Staff
